The pharmaceutical company FAES FARMA has entrusted OYTEC with the digitalisation of weighing operations at its pharmaceutical plants in Lamiako and Derio, Bilbao. Due to technological obsolescence, the existing dispensing system at the Lamiako plant needed to be replaced. Taking advantage of the construction of the new Derio plant, both plants will be equipped with a modern Electronic Dispensing system capable of working with the latest technologies in automated material handling and in-plant transport systems.
Founded in 1933, FAES FARMA is a Spanish pharmaceutical company with an extensive international track record that researches, produces and markets pharmaceutical products and raw materials, exporting to numerous countries.
The company’s hallmarks are an unwavering pursuit of excellence, a constant drive for the highest pharmacological quality in all its products and a consequent commitment to always offering highly effective solutions for its patients.
The new Electronic Weighing and Dispensing Guide system will provide additional functionality aligned with the needs of modern systems:
⦁ An electronic process flow for dispensing operations, as well as automation of cleaning procedures.
⦁ Electronic assurance of the sequenced addition of materials to process equipment
⦁ Real-Time Review by Exception of any deviation occurring during weighing, verification and sequenced addition, as well as during cleaning operations.
⦁ Automated material supply to the weighing rooms
⦁ Easily scalable to the entire plant with the Electronic Batch Record (eBR)
For more information, contact us at info@oytec.es
Latest News
Fast & Furious eBR Implementation
YES, that's right, a Fast & Furious eBR Implementation is possible. It is no longer a utopia to carry out an Electronic Batch Record implementation in a fast and massive way for any manufacturing plant. Regardless of the manufacturing area: bulk, weighing, or...
EMA and FDA: The 10 Principles of Pharmaceutical AI
The European Union and the United States published the Guiding Principles for Good AI Practices in Drug Development on January 14, 2026, as part of a strategic effort to harmonize regulatory criteria. The EMA-FDA collaborative work initiative has the mission of...
The FDA and Pharmaceutical AI: Key Points from the 2025 Draft on Model Credibility
The FDA positions credibility as an indispensable condition for utilising AI in pharmaceutical regulatory decision-making, within a risk-proportionate framework that demands traceability, transparency and validation throughout the entire model lifecycle. This approach...




